ArticleJournal of sleep research2026
Impact of Sleep Disturbances Treatment in Patients With Fibromyalgia: A Scoping Review.
Article in Journal of sleep research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia (FM) is a chronic clinical syndrome characterised by widespread musculoskeletal pain, fatigue and sleep disturbances, with non-restorative sleep being a central symptom that severely exacerbates the condition. Although management is multidisciplinary, the role of interventions specifically directed at sleep as a primary pathway to improve core FM symptoms requires systematisation. The objective of this scoping review was to map the therapeutic approaches, both pharmacological and non-pharmacological, that address sleep disturbances in FM patients, identifying their characteristics, outcomes and evidence gaps. The review was conducted in accordance with the JBI and PRISMA-ScR guidelines. The search, restricted to articles published between 2020 and 2024, was performed in the PubMed, SciELO and ScienceDirect databases, utilising descriptors such as 'fibromyalgia', 'sleep disorders' and 'therapeutics'. Nine studies met the inclusion criteria (six non-pharmacological, three pharmacological). Non-pharmacological interventions (including diet, manual therapies, and biofeedback) showed mixed results, often without a significant impact on primary sleep outcomes. Repetitive Transcranial Magnetic Stimulation (rTMS) and the drug Suvorexant stood out as the most promising strategies, demonstrating statistically significant improvement in both sleep quality (objective and subjective measures) and core FM symptoms. The field of study is characterised by high heterogeneity in interventions and outcomes, underscoring the need for high-quality Randomised Controlled Trials that utilise objective sleep measures as primary outcomes to provide robust evidence. The mapping provided by this review guides future research in optimising sleep treatment, a critical factor in managing FM and improving patients' quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.